Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02092649
Other study ID # 14JA044
Secondary ID
Status Completed
Phase N/A
First received March 17, 2014
Last updated December 1, 2015
Start date April 2014
Est. completion date January 2015

Study information

Verified date December 2015
Source University of Guelph
Contact n/a
Is FDA regulated No
Health authority Canada: Ethics Review Committee
Study type Interventional

Clinical Trial Summary

Fatty acids are the main components of the cell membranes. It has been demonstrated that diet can alter the characteristics and function of many membranes in the body, which has an effect on cardiovascular and metabolic health. Over the last two decades there has been a substantial rise in the research of the effects of Omega 3 polyunsaturated fatty acids on bodily function. There are two fatty acids that are of particular interest to researchers, eicosapentanoic acid (EPA) and docosahexanoic acid (DHA). These fatty acids have unique unsaturated structures, and their incorporation into biological membranes seems to generate important and positive physiological effects. The body is unable to synthesize these fatty acids in high concentrations to elicit significant effects, so they must be obtained through diet in food or via supplementation.

It has been suggested that EPA and DHA supplementation increases resting metabolic rate (RMR) in humans, in part by increasing the use of fat as a fuel during rest. There are a limited number of studies examining the effects of Omega 3 supplementation on RMR. Some have found an increase in RMR while others have found no change. These studies have some limitations, as that they have either used a small sample size, a low omega fatty acid dose and/or short supplementation periods. Due to the variable results, the investigators will improve the reliability of the RMR measurements by making measures on each subject during two consecutive days at each time point that it is measured (0, 6 and 12 weeks).

Therefore, the purpose of this study is to determine the effects of 12 weeks of omega 3 supplementation (3 g/d) on healthy young adults vs. the supplementation of a placebo. The researchers hypothesize that EPA and DHA supplementation will result in an increase in RMR and fat oxidation in some subjects and not in others. The duplicate RMR measures will determine the prevalence and magnitude of the omega 3 supplementation.


Recruitment information / eligibility

Status Completed
Enrollment 26
Est. completion date January 2015
Est. primary completion date November 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 30 Years
Eligibility Inclusion Criteria:

- 18 - 30 years of age.

- Must currently practice a consistent diet and exercise regimen, and maintain this throughout the duration of the study.

Exclusion Criteria:

- Current or previous supplementation with omega-3's.

- Average fish intake greater than two times per week.

- Taken any medications, have any medical condition, and hospitalization or surgeries.

- Allergy to fish/fish oil, , (rosemary extract, ascorbyl palmitate, or natural tocopherols).

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Omega-3 Complete

Placebo Pill


Locations

Country Name City State
Canada University of Guelph Guelph Ontario

Sponsors (1)

Lead Sponsor Collaborator
University of Guelph

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Resting Metabolic Rate From Baseline Percent change in resting metabolic rate Baseline, 6 weeks, 12 weeks No
Secondary Change in Maximum Oxygen Consumption From Baseline Baseline, 12 weeks No
Secondary Change in Whole Body Resting Fat Oxidation From Baseline Baseline, 6 weeks, 12 weeks No
Secondary Change in Whole Body Resting Carbohydrate Oxidation From Baseline Baseline, 6 weeks, 12 weeks No
Secondary Variability of Resting Metabolic Rate Measurement on 2 Consecutive Days Baseline, 6 weeks, 12 weeks No
Secondary Change in Fasted Blood Triglyceride Concentration From Baseline Baseline, 12 weeks No